Cargando…
RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases
BACKGROUND: Genetic biomarkers guide systemic anti-cancer treatment (SACT) in metastatic colorectal cancer. It has been suggested they have a role in selecting patients with colorectal peritoneal metastases (CRPM) for cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)...
Autores principales: | Bhullar, Dilraj, O’Dwyer, Sarah, Wilson, Malcolm, Saunders, Mark P., Kochhar, Rohit, Barriuso, Jorge, Aziz, Omer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807544/ https://www.ncbi.nlm.nih.gov/pubmed/36400886 http://dx.doi.org/10.1245/s10434-022-12704-9 |
Ejemplares similares
-
Predicting Early and Late Readmissions Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Moon, Eui Whan, et al.
Publicado: (2021) -
Coagulopathy and Venous Thromboembolic Events Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Dranichnikov, Paul, et al.
Publicado: (2021) -
Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis
por: Lee, Suk Jun, et al.
Publicado: (2021) -
Surgeons’ Ability to Predict the Extent of Surgery Prior to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
por: Hentzen, Judith E. K. R., et al.
Publicado: (2020) -
Survival Outcomes After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in Patients with Synchronous Versus Metachronous Onset of Peritoneal Metastases of Colorectal Carcinoma
por: Dietz, Michelle V., et al.
Publicado: (2022)